Diabetes and prognosis in a breast cancer cohort
暂无分享,去创建一个
M. Lux | K. Heusinger | M. Beckmann | P. Fasching | L. Häberle | C. Loehberg | A. Hein | C. Bayer | R. Schulz-Wendtland | B. Adamietz | A. Hartmann | M. Schrauder | C. Rauh | D. Wachter | J. Strehl
[1] R. Smith,et al. Breast cancer epidemiology. , 2018 .
[2] Mong-Hong Lee,et al. The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth , 2010, Journal of cellular and molecular medicine.
[3] M. Inoue,et al. Insulin resistance and cancer: Epidemiological evidence , 2010, Cancer science.
[4] D. Rose,et al. Interaction between menopausal status and obesity in affecting breast cancer risk. , 2010, Maturitas.
[5] C. Rock,et al. Medical comorbidities predict mortality in women with a history of early stage breast cancer , 2010, Breast Cancer Research and Treatment.
[6] D. Rose,et al. Influence of obesity on breast cancer receptor status and prognosis , 2009, Expert Review of Anticancer Therapy.
[7] Funda Meric-Bernstam,et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Donghui Li,et al. Premenopausal Breast Cancer: Estrogen Receptor Status and Insulin‐Like Growth Factor‐I (IGF‐I), Insulin‐Like Growth Factor Binding Protein‐3 (IGFBP‐3), and Leptin , 2009, The breast journal.
[9] Adrian V. Lee,et al. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. , 2009, Endocrine reviews.
[10] Thomas E Rohan,et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. , 2009, Journal of the National Cancer Institute.
[11] A. Wolff,et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. , 2008, JAMA.
[12] D. Leroith,et al. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. , 2008, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[13] M. Castiglione,et al. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] B. Zinman,et al. The impact of diabetes on survival following breast cancer , 2008, Breast Cancer Research and Treatment.
[15] R. Langer,et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. , 2008, Archives of internal medicine.
[16] D. Rose,et al. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer , 2007, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[17] Alicja Wolk,et al. Diabetes mellitus and risk of breast cancer: A meta‐analysis , 2007, International journal of cancer.
[18] Robert M Elashoff,et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. , 2007, Journal of the National Cancer Institute.
[19] R. Blamey,et al. EUSOMA accreditation of breast units. , 2006, European journal of cancer.
[20] Siegal Sadetzki,et al. Diabetes mellitus and breast cancer. , 2005, The Lancet. Oncology.
[21] E. Calle,et al. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.
[22] V. G. Pigmans,et al. Diabetes Mellitus Type 2 , 2004, Journal of the Epidemiology Foundation of India.
[23] M. Thun,et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. , 2004, American journal of epidemiology.
[24] S. Wild,et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.
[25] F. Pi‐Sunyer,et al. Obesity and type 2 diabetes. , 2003, Endocrinology and metabolism clinics of North America.
[26] JoAnn E Manson,et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. , 2003, Diabetes care.
[27] E. Bonora,et al. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. , 2003, Diabetes care.
[28] D. Rose,et al. Breast Cancer and Obesity: An Update , 2003, Nutrition and cancer.
[29] Donald L Weaver,et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] P. Porter,et al. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma , 2001, Cancer.
[31] E. Reiter,et al. Growth hormone , 1993 .
[32] M. La Guardia,et al. Breast cancer and obesity. , 2001, Panminerva medica.
[33] A. Green,et al. Cancer and diabetes ‐ a follow‐up study of two populationbased cohorts of diabetic patients , 1997, Journal of internal medicine.
[34] S. Greenland,et al. A Meta‐analysis of Body Mass Index and Risk of Premenopausal Breast Cancer , 1995, Epidemiology.
[35] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[36] R. Elashoff,et al. Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. The Women's Intervention Nutrition Study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] N. Boyd,et al. Body size and breast cancer prognosis: A critical review of the evidence , 1990, Breast Cancer Research and Treatment.
[38] G. Bray,et al. Obesity: definition, diagnosis and disadvantages , 1985, The Medical journal of Australia.
[39] K. Kliche,et al. Premenopausal Breast Cancer , 2012, Drugs.
[40] R. Kaaks,et al. Diabetes mellitus type 2 - an independent risk factor for cancer? , 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[41] B. Jasani,et al. ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS , 2009 .
[42] L. Pollack,et al. Therapy Insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer , 2005, Nature Clinical Practice Oncology.
[43] I. G. Fantus,et al. Insulin and related factors in premenopausal breast cancer risk , 2004, Breast Cancer Research and Treatment.
[44] B. Hoffman,et al. Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study , 2002 .
[45] B. Hoffman,et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.